Back to top
more

Medpace (MEDP)

(Real Time Quote from BATS)

$388.17 USD

388.17
9,023

+1.83 (0.47%)

Updated Jun 3, 2024 10:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut

by Zacks Equity Research

Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.

Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down

by Zacks Equity Research

Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.

STERIS (STE) Q2 Revenues Surpass Estimates, Margins Down

by Zacks Equity Research

STERIS' (STE) fiscal 2024 second-quarter results reflect continued momentum in the Healthcare business.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up

by Zacks Equity Research

Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.

Prestige Consumer (PBH) Q2 Revenues Top, Margins Expand

by Zacks Equity Research

Prestige Consumer's (PBH) second-quarter fiscal 2024 results benefit from a diverse brand portfolio and broad distribution.

Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down

by Zacks Equity Research

Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.

Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View

by Zacks Equity Research

Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.

Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Medpace (MEDP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

STERIS (STE) Set to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) second-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.

Tirthankar Chakraborty headshot

5 Stocks Worth a Buy for Remarkable Earnings Growth

by Tirthankar Chakraborty

Invest in stocks such as Hilton Worldwide (HLT), Stride (LRN), Costco Wholesale (COST), Medpace (MEDP) and H&E Equipment Services (HEES) for superb earnings growth.

Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View

by Zacks Equity Research

Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.

Hologic (HOLX) Q4 Earnings Might Rise on 7.7% Breast Health Growth

by Zacks Equity Research

Strength in Breast Health and growing Panther instrument installed base will likely benefit Hologic's (HOLX) Q4 performance.

Henry Schein (HSIC) Set to Post Q3 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) third-quarter 2023 results are likely to reflect the strong fundamentals of the Dental business.

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSMD

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

by Zacks Equity Research

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Medpace (MEDP) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 8.82% and 3.41%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

UnitedHealth Group's (UNH) Arm OptumRx Expands in Arizona

by Zacks Equity Research

UnitedHealth Group (UNH) is set to enhance the offerings of OptumRx with the recent expansion of pharmacy care services in Arizona.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi

by Zacks Equity Research

Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.

Are Medical Stocks Lagging Medpace (MEDP) This Year?

by Zacks Equity Research

Here is how Medpace (MEDP) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Fresenius Medical (FMS) Sinks on Potential Rise in Competition

by Zacks Equity Research

Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.